Acoustoelectric Echocardiography for Improving Prognosis & Guiding Treatment Decisions for Advanced Arrhythmias

摘要 心房颤动(AF)的特征是心房的无序激活导致心脏受损。 更严重的并发症，如栓塞性中风、恶化的心力衰竭和增加的死亡率。 AE影响了9%的美国人口(2%年龄在65岁以下)，并导致75万人住院和 每年有13万人死亡。显然，临床上对一种新的非侵入性成像方式的需求尚未得到满足 准确诊断、分类和定位房颤等晚期心律失常的起源，目的是使 更好的治疗决策和改善患者的结果。这项提议的目标是发展， 优化并验证第一个经胸声电心脏成像(TACI)系统，以实现实时、高性能 通过胸壁的心脏电流和心律失常的分辨率标测。这项专利技术结合了 具有高频射频记录以远程映射体内电流的超声波(例如， 心脏、大脑)在高分辨率下。如果成功，TACI将实现脑室的非侵入性电子标测 和心房，从而为晚期心律失常的分类提供了较高的诊断准确率 像房颤一样，定位其起源，指导治疗决策，减少医疗差错，带来更好的结果 对病人来说。ElectrSonix的长期目标是将革命性和便携的ACI商业化和转化为 将技术带到诊所、医生办公室和护理点，以改进所有类型的诊断和治疗 阿里斯米亚斯。到2020年，全球心脏诊断和监测设备市场预计将超过100亿美元 2020年，以4.0%的复合年增长率增长，而非侵入性诊断成像(例如心电)的特定市场是 预计到2025年，全球将以2.0%的复合年增长率达到10亿美元。一种基于TACI技术的临床系统 将极大地提高心律失常诊断和分类的准确性，从而对这一领域产生影响。此外， 通过定位心律失常的起源，拟议的临床TACI系统将有助于指导治疗决定， 减少医疗差错，提高房颤和其他晚期心律失常患者的生活质量。

ABSTRACT Atrial Fibrillation (AF) is characterized by a disorganized activation of the atrium leading to impaired cardiac function and more serious complications like embolic stroke, worsening heart failure, and increased mortality. AE affects 9% of the U.S. population (2% younger than 65) and contributes to 750,000 hospitalizations and 130,000 deaths per year. There is a clear unmet clinical need for a novel noninvasive imaging modality able to accurately diagnose, classify, and localize the origin of advanced arrythmias like AF with the goal of making better treatment decisions and improving patient outcomes. The objectives of this proposal are to develop, optimize, and validate the first transthoracic Acoustoelectric Cardiac Imaging (tACI) system for real-time, high resolution mapping of cardiac currents and arrythmias through the chest wall. This patented technology combines ultrasound with high frequency radiofrequency recording to remotely map electrical currents in the body (e.g., heart, brain) at high resolution. If successful, tACI will achieve noninvasive electrical mapping of the ventricles and atria at the mm and ms scales, thereby providing high diagnostic accuracy for classifying advanced arrythmias like AF, localizing its origins, guiding treatment decisions and reducing medical errors, leading to better outcomes for patients. The long-term goal at ElectroSonix is to commercialize and translate revolutionary and portable ACI technology to the clinic, doctor’s office, and point-of-care for improving diagnosis and treatment for all types of arrythmias. The global cardiac diagnostic and monitoring devices market is expected to surpass $10 billion by 2020, growing at 4.0% CAGR, while the specific market for noninvasive diagnostic imaging (e.g., ECG) is expected to reach $1 billion globally by 2025 at a CAGR of 2.0%. A clinical system based on tACI technology would impact this sector by greatly improving the accuracy for diagnosing and classifying arrythmias. Further, by localizing the origins of arrythmias, the proposed clinical tACI system would help guide treatment decisions, reduce medical errors, and improve quality of life for patients suffering from AF and other advanced arrythmias.